Picture of CJ Bioscience logo

311690 CJ Bioscience Cashflow Statement

0.000.00%
kr flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

Annual cashflow statement for CJ Bioscience, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

2021
December 31st
2022
December 31st
2023
December 31st
2024
December 31st
2025
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:Annual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited Accounts
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-19,272-34,913-22,913-32,838-24,005
Depreciation
Amortisation
Non-Cash Items10,2783,138-8,002144436
Unusual Items
Other Non-Cash Items
Changes in Working Capital-1,0056,883870613-3,860
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities-8,437-20,993-24,899-27,760-23,416
Capital Expenditures-979-4,870-16,417-584-75.9
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items7,43112,03533,116-66,97426,980
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Change in Net Intangibles
Other Investing Cash Flow
Cash from Investing Activities6,4537,16516,699-67,55726,904
Financing Cash Flow Items-250-261-312-363
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities50,7111,02222,94439,499-1,442
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash48,805-12,73714,772-55,7862,030